Levalbuterol tartrate

Levalbuterol Tartrate is the tartrate salt form of levalbuterol, the R-enantiomer of the short-acting beta-2 adrenergic receptor agonist albuterol, with bronchodilator activity. Levalbuterol selectively binds to beta-2 adrenergic receptors in bronchial smooth muscle, thereby activating intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cAMP). Increased cAMP levels cause relaxation of bronchial smooth muscle, relieve bronchospasms, improve mucociliary clearance and inhibit the release of mediators of immediate hypersensitivity from cells, especially from mast cells. It is grouped under the following drug class(es): Bronchodilators. Its therapeutic use is listed as anti-asthmatic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Xopenex HFA and Levosalbutamol tartrate. Its PubChem CID is 10349032.

CAS No 661464-94-4
Molecular Formula C30H48N2O12
Molecular Weight 628.70 g/mol
Synonyms bis(4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol);(2R,3R)-2,3-dihydroxybutanedioic acid

Frequently Asked Questions